Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Malvi Savani; Katti Woerner; Lihong Bu; Mark Birkenbach; Keith M. Skubitz

doi:10.1007/s00280-020-04203-z

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Malvi Savani, Katti Woerner, Lihong Bu, Mark Birkenbach, Keith M. Skubitz

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.

Original language	English (US)
Pages (from-to)	289-294
Number of pages	6
Journal	Cancer chemotherapy and pharmacology
Volume	87
Issue number	2
DOIs	https://doi.org/10.1007/s00280-020-04203-z
State	Published - Feb 2021

Bibliographical note

Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords

Doxorubicin
Renal toxicity
Sarcoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/s00280-020-04203-z

OpenUrl availability

Full text

Cite this

@article{5478d924c4f0468ea1c3b656374fec61,

title = "Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review",

abstract = "Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.",

keywords = "Doxorubicin, Renal toxicity, Sarcoma",

author = "Malvi Savani and Katti Woerner and Lihong Bu and Mark Birkenbach and Skubitz, {Keith M.}",

note = "Publisher Copyright: {\textcopyright} 2021, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = feb,

doi = "10.1007/s00280-020-04203-z",

language = "English (US)",

volume = "87",

pages = "289--294",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma

T2 - a case report and literature review

AU - Savani, Malvi

AU - Woerner, Katti

AU - Bu, Lihong

AU - Birkenbach, Mark

AU - Skubitz, Keith M.

PY - 2021/2

Y1 - 2021/2

N2 - Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.

AB - Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.

KW - Doxorubicin

KW - Renal toxicity

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85098557098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098557098&partnerID=8YFLogxK

U2 - 10.1007/s00280-020-04203-z

DO - 10.1007/s00280-020-04203-z

M3 - Article

C2 - 33388949

AN - SCOPUS:85098557098

SN - 0344-5704

VL - 87

SP - 289

EP - 294

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 2

ER -

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this